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Changes in DNA copy number, whether confined to specific genes or affecting whole chromo-
somes, have been identified as causes of diseases and developmental abnormalities and as sour-
ces of adaptive potential. Here, we discuss the costs and benefits of DNA copy-number alterations.
Changes in DNA copy number are largely detrimental. Amplifications or deletions of specific genes
can elicit discrete defects. Large-scale changes in DNA copy number can also cause detrimental
phenotypes that are due to the cumulative effects of copy-number alterations of many genes simul-
taneously. On the other hand, studies in microorganisms show that DNA copy-number alterations
can be beneficial, increasing survival under selective pressure. As DNA copy-number alterations
underlie many human diseases, we will end with a discussion of gene copy-number changes as
therapeutic targets.Introduction
Every species is defined by its karyotype. Maintaining this karyo-
type is essential for species survival, a truth perhaps best illus-
trated by the fact that numerous mechanisms have evolved to
ensure that the species-specific karyotype is maintained.
Changes in the copy number of specific genes, entire chromo-
somes, or parts thereof can have a dramatic impact on the
fitness and reproductive abilities of an organism. Trisomy 21 in
humans illustrates this point. Individuals with trisomy 21, also
known as Down syndrome, exhibit a number of developmental
disabilities and have a significantly reduced life span (Yang
et al., 2002). The fact that changes in copy number of small
regions of the genome can have a significant impact on fitness
is emphasized by genome-wide association studies of geneti-
cally complex human diseases. Small-scale often submicro-
scopic changes in DNA copy number are estimated to be
responsible for at least 15% of human neurodevelopmental
defects and are associated with psychiatric disorders and
kidney and heart defects (reviewed in Girirajan et al., 2011).
Much progress has been made in our ability to identify DNA
copy-number alterations and to determine their biological
impact. Depending on their size, DNA copy-number alterations
are referred to by different terms (Figure 1). Multiples of the entire
genetic complement are referred to as polyploidies. Whole-
chromosome (34 230 Mbp) gains or losses are known as
aneuploidies (Figures 1A and 1C). Changes in copy number of
subchromosomal regions that are visible by light microscopy
are referred to as partial or segmental aneuploidies. Submicro-
scopic DNA copy-number alterations that are between 1 kbp
and 1 Mbp in length are referred to as copy-number variations
(CNVs; Figures 1A and 1B). Smaller changes in DNA copy
number—ranging 1 bp to 1 kbp in size—are called deletions or
insertions depending on whether sequences are deleted or394 Cell 152, January 31, 2013 ª2013 Elsevier Inc.amplified, respectively (Figure 1A) (Feuk et al., 2006; Lupski,
2007). The mechanisms leading to small- and large-scale DNA
copy-number changes have been investigated in detail. We refer
the reader to several excellent recent reviews that summarize
our current understanding of these mechanisms (Alkan et al.,
2011; Holland and Cleveland, 2012; Malhotra and Sebat, 2012;
Zhang et al., 2009).
Here we discuss the costs and benefits of small- and large-
scale DNA copy-number alterations. We will describe examples
that illustrate how copy-number alterations of individual genes
can result in cellular and organismal abnormalities. We will
further discuss findings that show that large-scale DNA copy-
number changes, such as whole-chromosome gains and losses,
cause general, detrimental phenotypes that result from the
cumulative effects of changes in copy number of a large number
of genes. The potential benefits of gene copy-number alterations
will also be examined, summarizing studies that show that gene
copy-number alterations can improve survival of microorgan-
isms under selective pressure. Finally we will consider the possi-
bility of targeting gene copy-number changes in the treatment of
human diseases.
The Impact of Copy-Number Changes on Gene
Expression
Before considering the biological impact of changes in gene
copy number, it is important to address the question of whether
such changes are translated into corresponding changes in gene
expression or whethermechanisms are in place that ensure wild-
type levels of expression irrespective of gene copy number.
Such mechanisms, collectively called dosage-compensation
mechanisms, exist for sex chromosomes, which naturally vary
in copy number between sexes (reviewed in Nguyen and
Disteche, 2006). With the exception of Drosophila and some
Figure 1. Defining DNA Copy-Number Alterations
(A) DNA copy-number alterations can be categorized into submicroscopic variations, which are smaller than 500 kbp, and microscopic alterations, which are
greater than 500 kbp. DNA copy-number changes between 1 bp and 1 kbp in size are called insertions or deletions, depending on whether DNA is gained or lost,
respectively. Copy-number variations (CNVs) vary between 1 kbp and 1 Mbp in size. Examples for CNVs are shown for duplication. Microscopically visible
karyotype changes are called segmental or partial aneuploidies, when parts of chromosomes are amplified or deleted. Whole-chromosome losses or gains are
called aneuploidies.
(B) CNV distribution on human chromosome 1. Dots show the number of individuals with copy gains (blue) or losses (red) among 39 unrelated, healthy control
individuals (data from Iafrate et al., 2004).
(C) Spectral karyotyping (SKY) analysis of a trisomy 16 MEF cell line (data from Williams et al., 2008) and a MCF7 breast cancer cell line (data from http://www.
path.cam.ac.uk/pawefish/BreastCellLineDescriptions/mcf7.htm).plant species (Guo and Birchler, 1994; Kim et al., 2011; Larsson
et al., 2001; Miclaus et al., 2011; Stenberg and Larsson, 2011),
dosage-compensation mechanisms do not exist for autosomes.
Gene copy-number proportional expression of whole chromo-
somal or segmental aneuploidies has been observed in fission
yeast, budding yeast, Arabidopsis, trisomic mouse embryonic
fibroblasts (MEFs), partially trisomic mouse tissues, and human
trisomies (Chikashige et al., 2007; Huettel et al., 2008; Kahlem
et al., 2004; Lyle et al., 2004; Pavelka et al., 2010; Torres et al.,
2007; Upender et al., 2004; Vacı´k et al., 2005; Williams et al.,
2008; Stingele et al., 2012) (Figure 2). CNVs also typically result
in a corresponding change in gene expression. In humans and
mice, 85%–95% of CNVs are associated with changes in
expression of the affected genes (Henrichsen et al., 2009;
Stranger et al., 2007).
In organisms where this has been studied, increases in RNA
levels result in increased protein production. Quantitative pro-
teomic analyses in aneuploid budding yeast and human cells
showed that changes in gene copy number result in changes
in protein levels in the majority of cases (Pavelka et al., 2010;Stingele et al., 2012; Torres et al., 2010). The proteins that do
not show this coordinate increase in protein levels with gene
copy number are predominantly components of large protein
complexes (Stingele et al., 2012; Torres et al., 2010), presumably
because unassembled subunits of protein complexes are often
unstable. Thus, gene copy-number changes generally translate
into changes in gene expression.
The Biological Impact of DNA Copy-Number Alterations
Changes in DNA copy number generally have adverse effects on
fitness. The degree of adversity scales with the size of the alter-
ation. Whole-chromosome and segmental aneuploidies invari-
ably lead to severe developmental abnormalities or death of
the organism in all species analyzed to date (reviewed in Torres
et al., 2008). CNVs are, for the most part, also detrimental.
Sequencing of human populations revealed that CNVs are rare,
occurring at a frequency of less than 1% (Itsara et al., 2009),
and that they are under strong negative selection (Itsara et al.,
2010). Insertions and deletions on the other hand are widespread
in the human genome, indicating that their impact on fitness isCell 152, January 31, 2013 ª2013 Elsevier Inc. 395
Figure 3. Gene-Specific and General Effects of Aneuploidy on
Fitness
X means observed, empty box means that this has not been examined. See
text for details.
Figure 2. Aneuploid Chromosomes Are Active in Budding Yeast
DNA, RNA, and protein content of a budding yeast strain carrying an additional
copy of chromosome 5 (data from Torres et al., 2010).likely to be minor (Girirajan et al., 2011; Iafrate et al., 2004; Sebat
et al., 2004).
How do changes in gene copy number lead to phenotypes?
Changes in the copy number of individual genes can cause
phenotypes. Phenotypes can also be driven by the cumulative
effect of changes in copy number of a large number of genes,
which individually have little or no effect. In this section we will
discuss the gene-specific and general effects of changes in
DNA copy number.
Gene-Specific Effects
It has long been known that changes in the copy number of
specific genes can have a dramatic impact on organismal and
cellular fitness. For example, budding yeast cells harboring an
extra copy of the b-tubulin-encoding gene are inviable (Katz
et al., 1990). Studies in humans suggest that as many as 15%
of neurodevelopmental disorders and other diseases are due
to rare, large CNVs resulting in the imbalance of a handful of
genes (for a recent review, see Malhotra and Sebat, 2012). For
example, duplication of PMP22 leads to Charcot-Marie-Tooth
1A neuropathy (reviewed in Hanemann and Mu¨ller, 1998).
Duplication of SNCA is associated with Parkinson’s disease
(Singleton et al., 2003), duplication of GSK3b with bipolar
disorder (Lachman et al., 2007), and low-copy amplification of
the C4 gene with lupus (Yang et al., 2007). Finally, amplifications
and deletions of individual genes are major drivers of tumorigen-
esis. Amplification of the oncogene Myc, for example, is thought
to be a driving factor in human acute myeloid leukemia (AML)
(Jones et al., 2010).
Gene-dosage changes of individual genes also appear to be
responsible for some of the phenotypes observed in syndromes
caused by chromosome-size DNA copy-number changes.
For example, chromosome 21-located APP, which encodes a
protein that when cleaved forms the main component of
amyloid-b plaques, has been found to be duplicated in familial
forms of early onset Alzheimer’s disease. This observation sug-
gests that early onset Alzheimer’s disease, which is observed in
virtually all individuals with Down syndrome, is due to a second396 Cell 152, January 31, 2013 ª2013 Elsevier Inc.copy of APP (reviewed in Kingsbury et al., 2006). Many more
examples have been described where imbalances in the copy
number of one or a few genes elicit a discrete phenotype, and
we refer the reader to recent reviews that provide a comprehen-
sive overview of the contribution of gene copy-number changes
to human diseases (Girirajan et al., 2011; Zhong et al., 2009).
General Non-Gene-Specific Effects of Large-Scale DNA
Copy-Number Alterations
Changes in the copy number of large regions of the genome can
also cause phenotypes that are the result of cumulative effects of
copy-number changes in many genes, which on their own have
little phenotypic consequences. Studies on whole-chromosome
gains in yeast and mammalian cells revealed phenotypes that
are seen inmany different aneuploidies (summarized in Figure 3).
The severity of these phenotypes tends to scale with the degree
of deviation from the euploid karyotype, and thus they likely also
exist in cells harboring large segmental aneuploidies, but not
in cells with CNV-size DNA copy-number alterations. In the
following section, we will describe the general phenotypes asso-
ciated with large-scale DNA copy-number alterations.
(A) Whole-Chromosome Copy-Number Alterations
Interfere with Cell Proliferation
Studies of S. pombe and S. cerevisiae aneuploid strains (Niwa
et al., 2006; Pavelka et al., 2010; Torres et al., 2007) showed
that aneuploidy impairs proliferation under standard growth
conditions. Similar slowed growth was observed in mammalian
cells. Trisomic MEFs exhibit proliferation defects, as do
cells harboring random aneuploidies caused by mutations of
BubR1 or Cdc20 that lead to increased chromosome mis-
segregation (Baker et al., 2004; Li et al., 2009; Thompson and
Compton, 2008; Williams et al., 2008). These adverse effects
on cell proliferation have severe consequences for the animal.
Mice expressing mutations leading to high levels of chromo-
some missegregation die in utero or exhibit premature aging
phenotypes (Baker et al., 2004; Li et al., 2009). In humans,
hypomorphic mutations in BubR1 lead to mosaic-variegated
aneuploidy, which is associated with growth deficiency and
short stature, mental retardation, developmental defects, as
well as a predisposition to cancer (Hanks et al., 2004). Several
mouse models of chromosome instability (CIN) do not exhibit
dramatic defects in cell proliferation, and animals show little if
any decline in overall fitness (reviewed in Pfau and Amon,
2012), indicating that some level of aneuploidy can be tolerated
and perhaps compensated for by cells especially in the context
of the organism, where proliferative potential is frequently not
rate limiting.
How large-scale copy-number changes such as chromosomal
gains or losses interfere with cell proliferation is not understood.
In budding yeast, fission yeast, and human cells, chromosome
gains cause a G1 delay (Niwa et al., 2006; Torres et al., 2007;
Stingele et al., 2012). Many stresses cause a transient G1 delay,
by impacting the cell-cycle machinery governing the G1–S
phase transition. Gross copy-number changes elicit phenotypes
that are reminiscent of a stress response (see below). The
observed G1 delay could thus be part of such a stress response.
It is, however, also possible that a different genetic imbalance
underlies each G1 delay in the different aneuploid strains. In
mammalian cells, chromosome missegregation and the ensuing
aneuploidy cause activation of p53, which results in G1 arrest or
apoptosis (Li et al., 2010; Thompson and Compton, 2010). The
origins of this p53 response are controversial but could be due
to various aneuploidy-associated stresses, which are discussed
in the following section.
(B) Whole-Chromosome Copy-Number Alterations
Cause Several Cellular Stresses, Collectively Called
the ‘‘Aneuploidy-Associated Stresses’’
Studies in aneuploid yeast and MEFs indicate that aneuploid
cells experience metabolic stress. Yeast cells and MEFs with
unbalanced karyotypes produce less biomass (Li et al., 2010;
Torres et al., 2007; Williams et al., 2008). Trisomic MEFs and
MEFs containing the aneuploidy-inducing CDC20AAA mutation
were also found to take up more glutamine and to exhibit sensi-
tivity to the energy stress-inducing compound AICAR (Li et al.,
2010; Tang et al., 2011; Williams et al., 2008). Aneuploid cells
generated by the CDC20AAA mutation also display increased
glucose uptake and lactate production (Li et al., 2010). In all,
these findings point toward increased energy needs of cells
with large-scale karyotypic changes. Perhaps, cells wasteenergy by producing and then dealing with the excess proteins
produced from the additional genes.
Because gains and losses of genetic information impact gene
expression, large-scale changes in gene copy number have
a profound impact on the cell’s protein composition. Overpro-
duced proteins and proteins lacking their appropriate binding
partners eventually misfold and lead to a condition known as
proteotoxic stress. Thus, not surprisingly, cells with whole-
chromosome gains are under proteotoxic stress. Aneuploid
S. cerevisiae cells are more sensitive to conditions that elicit pro-
teotoxic stress such as elevated temperature or treatment with
the protein-synthesis inhibitors cycloheximide or hygromycin
and the Hsp90 inhibitor geldanamycin (Pavelka et al., 2010;
Torres et al., 2007). Furthermore, aneuploid yeast cells form
protein aggregates and appear challenged in their ability to
fold proteins (Oromendia et al., 2012). In addition, inactivation
of the proteasome antagonist Ubp6 improved the fitness of
several different yeast strains carrying an additional chromo-
some and partially attenuated the proteomic changes elicited
by the aneuploid karyotype (Torres et al., 2010). Evidence for
proteotoxic stress also exists inmammalian cells harboring addi-
tional chromosomes. Trisomic MEFs and human cells show
increased basal levels of autophagy and the chaperone Hsp72
and are more sensitive to the Hsp90 chaperone inhibitor 17-
AAG than euploid cells (Stingele et al., 2012; Tang et al., 2011).
In summary, changes in gene copy number ofmany genes simul-
taneously, as occurs when entire chromosomes are lost or
gained, profoundly alter the cell’s protein composition. This
aneuploidy-induced change in the cell’s proteome places
a burden on the cell’s protein quality-control pathways and
hence impacts fitness.
(C) Large-Scale Changes in DNACopy NumberMay Elicit
a Stress Response
Whole-chromosomal aneuploidies have been shown to lead to
a transcriptional response in all organisms where this has been
analyzed. A gene-expression signature similar to the environ-
mental stress response (ESR) in budding yeast has been found
to exist not only in aneuploid budding yeast strains (Torres
et al., 2007) but also in fission yeast, Arabidopsis, mouse, and
human cells with whole-chromosome gains (Sheltzer et al.,
2012). The ESR was first defined in budding yeast. The ESR
gene-expression signature is characterized by genes involved
in the response to stress being upregulated and genes associ-
ated with cell growth and proliferation being downregulated
(Gasch, 2007). The ESR is elicited by a large number of stress
conditions and is associated with slow growth (Brauer et al.,
2008; Gasch et al., 2000; Regenberg et al., 2006). The finding
that an ESR-like gene-expression pattern exists in many
different whole-chromosome aneuploidies in different organ-
isms raises the interesting possibility that aneuploidy affects
similar cellular pathways and causes an antiproliferative re-
sponse in most if not all organisms.
In addition to an ESR-like transcriptional response, several
studies indicate that in mammalian cells, p53 is activated in
response to chromosome missegregation and/or aneuploidy,
though the proposed mechanisms differ. The first study to impli-
cate p53 in antagonizing the proliferation of cells that missegre-
gate chromosomes or that are aneuploid examined mouseCell 152, January 31, 2013 ª2013 Elsevier Inc. 397
embryos lacking the spindle assembly checkpoint component
MAD2. Such embryos die by embryonic day (E) 7.5 due to
massive chromosome missegregation, but deletion of p53
permits such embryos to survive until E10.5 (Burds et al., 2005;
Dobles et al., 2000). In 2010, Thompson and Compton showed
that the process of missegregating chromosomes leads to acti-
vation of p53 through the stress kinase p38 (Thompson and
Compton, 2010). Li et al. (2010) also observed p53 activation
upon chromosomemissegregation but suggested that the accu-
mulation of reactive oxygen species (ROS) was responsible for
p53 activation (Li et al., 2010). ROS, generated by increased
metabolism in aneuploid cells, activate the DNA-damage check-
point kinase ATM in a DNA-damage-independent manner
(Li et al., 2010). ATM in turn activates p53. Interestingly, the
authors of this study also found that p53 activity is correlated
with aneuploidy level. A low degree of aneuploidy caused
a less pronounced p53 response than high levels. This graded
response to aneuploidy may explain why p53 activity was not
found to be increased in trisomic MEFs, in which the degree of
aneuploidy is low, and cells have had time to adapt to the aneu-
ploid state prior to analysis (Tang et al., 2011).
The studies that observed a p53 response in aneuploid cells
did not examine cells with constitutive aneuploidies but cells
that actively missegregate chromosomes, a condition known
as CIN. p53 activation may thus not be a consequence of aneu-
ploidy per se but could also be caused by events associated with
chromosome missegregation. This is the conclusion that Jans-
sen et al. (2011) arrived at. Their studies suggest that the process
of missegregating a chromosome leads to lagging chromo-
somes, which suffer DNA damage during cytokinesis. This cyto-
kinesis-inflicted DNA damage in turn causes p53 activation
through the canonical DNA-damage pathway (Janssen et al.,
2011). It should further be noted that cytokinesis failure even in
the absence of DNA damage can cause p53 activation (de
Stanchina et al., 1998; Serrano et al., 1997). Consistent with
the idea that p53 activation may be a consequence of chromo-
somemissegregation rather than aneuploidy per se is the obser-
vation that in cells harboring whole-chromosome gains without
accompanying CIN, a p53 response has not been detected.
Trisomic MEFs do not mount a p53 response (Tang et al.,
2011). Thus it remains to be determined whether p53 activation
is a response to chromosome missegregation-induced DNA
damage or cytokinesis defects, to the aneuploid state, or to all
of the above. Although the exact function of p53 in CIN and aneu-
ploidy remains to be determined, it is clear that mechanisms
other than p53 activation also limit the proliferation of cells
harboring aneuploidies or other large-scale gene copy-number
changes. Trisomic MEFs proliferate poorly without mounting
a p53 response (Tang et al., 2011).
(D) Aneuploidy and CIN Cause Genome Instability
It has recently become clear that the presence of additional chro-
mosomes as well as the process of gaining or losing whole
chromosomes have a dramatic effect on genome stability.
Budding yeast strains harboring additional chromosomes exhibit
increased rates of chromosome missegregation, mitotic recom-
bination, mutation, and DNA damage, as well as increased
sensitivity to genotoxic agents (Sheltzer et al., 2011; Zhu
et al., 2012). Aneuploid fission yeast cells are also sensitive to398 Cell 152, January 31, 2013 ª2013 Elsevier Inc.DNA-damaging agents and harbor an increased number of
DNA-damage foci (Sheltzer et al., 2011). The origins of these
genome instability-inducing effects ofwhole-chromosome aneu-
ploidies are not yet known but have been suggested to be due
to changes in the copy numbers of specific genes. For example,
changes in the dosage of the gene encoding the kinesin
Kip3 impact mitotic spindle dynamics and cause increased
chromosome missegregation in budding yeast (Su et al., 2011).
Changes in gene copy number also impact the stability of their
immediate environment. Repeated DNA sequences are prone
to engage in nonallelic homologous recombination especially
during meiosis, which can lead to genomic rearrangements.
Two recent studies in mammalian cells showed that
the process of changing the copy number of whole chromo-
somes, chromosome missegregation, also induces genomic
instability, especially DNA damage. Merotelically attached
chromosomes—these are chromosomes that attach to microtu-
bules emanating from both centrosomes—remain in the center
of the cell during anaphase (Janssen et al., 2011; Thompson
and Compton, 2010). These lagging chromosomes are then
broken during cytokinesis, which leads to translocations and
other genomic rearrangements (Janssen et al., 2011).
Chromosome breaks on lagging chromosomes not only occur
because of breakage of the chromosome during cytokinesis,
they also form because of their inefficient replication in the
subsequent cell cycle (Crasta et al., 2012). Lagging chromo-
somes can form micronuclei if they fail to reach the bulk of the
segregated DNA prior to nuclear-envelope reformation. These
micronuclei then undergo defective and asynchronous DNA
replication, which results in DNA damage and fragmentation
and rearrangement of the chromosome in the micronucleus.
This phenomenon could explain a recently discovered fea-
ture of some cancers, called chromothripsis, where individual
chromosomes undergo massive breakage and rearrangement
(Stephens et al., 2011). Amplifications, deletions, and whole-
chromosome gains or losses are a hallmark of cancer. The
genome-instability-inducing effects of chromosome missegre-
gation and the resulting whole-chromosomal aneuploidies
could fuel the dramatic karyotype changes characteristic of
tumorigenesis.
(E) Are Some Developmental Defects Seen in Aneuploid
Organisms due to the General Effects Caused by Large-
Scale Gene Copy-Number Alterations?
In cells changes in chromosome copy number elicit a set of
phenotypes that appears to be independent of the identity of
the genes whose copy numbers are altered. Are such general
phenotypes also evident at the organismal level? Most organ-
isms with whole-chromosome aneuploidies or large segmental
aneuploidies are growth retarded (reviewed in Torres et al.,
2008), which is most likely due to the impact of large-scale
gene copy-number alterations on cell proliferation (see above).
Beyond the stunted growth, few commonalities are observed
among different aneuploids at the organismal level. This finding
indicates that most developmental aberrations observed in
organisms with large-scale DNA copy-number alterations are
due to copy-number changes of specific genes. However, it is
intriguing to note that in mammals, some developmental pheno-
types are observed in many different trisomies. Mice and
Figure 4. Effects of Increasing and Decreasing Gene Copy Number
(A) Increasing or decreasing the levels of most genes by 50% has a minimal
impact on fitness, but decreases or increases beyond that can affect fitness
(based on Kacser and Burns, 1981).
(B) Changing the copy number of structural genes can have dramatic effects.
The example of the b-tubulin-encoding gene is shown (Katz et al., 1990).humans trisomic for any chromosome exhibit craniofacial
defects such as cleft palate, microcephaly, cardiac defects,
and nuchal edema (Gropp et al., 1975; Hassold and Jacobs,
1984; Krushinskiĭ et al., 1986). It may simply require a large
number of dosage-sensitive genes to build the organs whose
development is affected in many different aneuploidies, but it
is also possible that some general aspects of large-scale gene
copy-number changes affect pathways used in the development
of these organs.
In summary, the phenotypic analyses of small- and large-scale
changes in DNA copy number lead to two general conclusions.
First, changes in the copy number of single or a small number
of genes can lead to specific phenotypes, as illustrated by
human diseases such as Charcot-Marie-Tooth 1A neuropathy
or APP-driven early onset Alzheimer’s disease. Second, when
the copy number of large genomic regions is altered, such as
in whole-chromosome aneuploidies, the origins of the pheno-
types are more complex. Some phenotypes are the result of
cumulative effects of changes in copy number of a large number
of genes, whereas others are caused by changes in the dosage
of single genes.
Why Are Gene Copy-Number Alterations Detrimental?
Although it is possible that in some circumstances, changes in
specific DNA sequences (i.e., centromeres or telomeres) can
have adverse effects (Futcher and Carbon, 1986; Runge and
Zakian, 1989), the most likely explanation for the majority of
detrimental phenotypes caused by changes in gene copy
number is the gene dosage hypothesis: gains or losses of gene
copies change the expression levels of the affected gene. This
altered dosage impacts fitness. The comparison of the pheno-
types caused by changing the copy number of autosomes and
sex chromosomes illustrates this point. The consequences of
losing or gaining autosomes, for which dosage compensation
does not occur, are severe. Alterations in sex chromosome
copy number, for which dosage compensation occurs, are
mild (reviewed in Berletch et al., 2011; Prestel et al., 2010).
We can envision several ways in which an altered gene dosage
can negatively impact cellular or organismal fitness:
(1) Dramatic over- or underexpression of a specific gene can
cause phenotypic changes (Figures 4A and 5A). The recurrentamplifications of c-Myc or of receptor tyrosine kinases in various
tumors are examples of such effects.
(2) Changing the levels of individual genes encoding structural
proteins or proteins that function in protein complexes by 50%
can affect fitness (Kacser and Burns, 1981; Veitia, 2002) (Figures
4B and 5B).
(3) Overexpression of individual genes that encode proteins
that engage in promiscuous low-affinity interactions can result
in off-target interactions, thereby impairing fitness (Vavouri
et al., 2009) (Figure 5C).
(4) The detrimental phenotypes associated with gene copy-
number changes can also result from synergistic effects of
large-scale DNA copy-number alterations. Overexpression of
many proteins at once can impact basic cellular functions such
as energy homeostasis and protein quality-control mechanisms
(Figure 5D). In the absence of sufficient chaperone capacity to
accommodate overexpressed proteins, other chaperone clients
that fail to fold in a timely manner will be degraded or deposited
as aggregates (Olzscha et al., 2011) (Figure 5D). Protein stoichi-
ometry imbalances caused by gene copy-number changes can
also contribute to proteotoxicity. Many subunits of protein
complexes only acquire a stable conformation by binding to
other subunits of the complex (Kaizu et al., 2010; Vavouri et al.,
2009). Thus, changes in dosage of genes encoding polypeptides
that normally have binding partners will produce excess proteins
that require the continuous assistance of chaperones, prevent-
ing chaperones from assisting other folding reactions. This could
reduce the general folding capacity of the cell and thus interfere
with their essential function of mediating folding of essential
proteins (Olzscha et al., 2011). Indeed, the production of a mis-
folded protein representing 0.1% of the total yeast proteome
leads to a significant reduction in fitness and elicits a cytoplasmic
unfolded protein response (Geiler-Samerotte et al., 2011).
Excess proteins also impact proteasomal degradation, as
excess proteins are frequently cleared by ubiquitin-proteasomal
degradation (Figure 5D). Energy stress may also exist in cells
with large-scale DNA copy-number alterations. The production
of additional gene products and the shielding of the cell from
the effects cost energy. This increased energy demand may
negatively impact fitness.
Gene Copy-Number Alterations as a Source of Adaptive
Potential and Their Function during Normal
Development
Gene copy-number changes are not always detrimental. Exper-
imental evolution studies demonstrate that under selection, gene
copy-number changes endow the organism with increased
survival under the imposed selection. Perhaps the best example
of such beneficial effects is the tissue-specific amplification of
genes as part of normal development.
DNA Copy-Number Changes as a Source of Adaptive
Potential
In 1981, Edlund and Normark reported that amplification of the
ampC locus promotes antibiotic resistance in E. coli (Edlund
and Normark, 1981). Many subsequent studies have shown
that gene amplifications frequently arise during adaptive evolu-
tion experiments. For example, in budding yeast, growth under
glucose limitation selects for cells in which the genesCell 152, January 31, 2013 ª2013 Elsevier Inc. 399
Figure 5. Consequences of Changes in Gene Copy Number
(A) An increased dosage of a single gene, such as a rate-limiting enzyme B, can increase the output or function of a cellular pathway. Conversely, reduction of
enzyme B will diminish the production of C, thus decreasing pathway activity.
(B) Altered gene dosage can interfere with the function of stoichiometry-sensitive complexes, with excess of protein A or protein B inhibiting the function of C and
therefore decreasing pathway activity.
(C) Overexpression of a regulatory enzyme can lead to off-target effects. For example, overexpression of a protein kinase or protein phosphatase can cause
deregulation of pathways that proteins usually do not function in.
(D) Changes in the copy number of many genes simultaneously can impact protein quality-control mechanisms such as molecular chaperones and the ubiquitin-
proteasome system (UPS). Misfolded proteins can eventually form aggregates.encoding high-affinity glucose transporters are amplified (Brown
et al., 1998; Dunham et al., 2002; Kao and Sherlock, 2008)
(Figure 6A). Studies employing other nutrient-deprivation selec-
tions revealed similar principles; genes that facilitate the uptake
and/or metabolism of the limiting factor are upregulated often
through gene amplification (Gresham et al., 2008, 2010). This
principle is recapitulated during tumorigenesis. Amplifications
of oncogenes and losses of tumor-suppressor genes are an inte-
gral feature of the disease (Gordon et al., 2012).
Whole-chromosome and segmental aneuploidies are also ob-
tained in experimental evolution experiments because a gene in
that genomic region provides a selective advantage. For
example, the pathogenic fungus C. albicans can develop resis-
tance to the antifungal drug fluconazole through duplication of
the left half of chromosome 5 (Selmecki et al., 2006). This region
of chromosome 5 harbors ERG11, which encodes the biosyn-
thetic enzyme targeted by fluconazole, as well as TAC1, a tran-
scription factor that upregulates expression of (ABC) transporter
genes (Selmecki et al., 2006). Their duplication is an important
contributor to fluconazole resistance in strains harboring the
segmental aneuploidy of chromosome 5. In budding yeast,
whole-chromosome aneuploidies have been obtained in the
selection for suppressors of cytokinesis defects (Rancati et al.,
2008). These aneuploidies occurred in the context of an increase
in base ploidy. Polyploid cells exhibit increased CIN (Storchova´
et al., 2006), indicating that polyploidization predisposes to
aneuploidy. Polyploidy not only may facilitate the generation of
aneuploidy (Storchova´ et al., 2006), it also attenuates the pheno-
types associated with the condition (Torres et al., 2007) and may
thus buffer against the adverse effects of aneuploidy, allowing
cells to take full advantage of potential beneficial effects associ-
ated with certain gene copy-number alterations. This could400 Cell 152, January 31, 2013 ª2013 Elsevier Inc.explain why cancer cells, which are highly aneuploid, often
show increased base ploidy.
The selective advantage gained through whole-chromosome
aneuploidies comes at a price. A large-scale DNA copy-number
alteration results in changes in the dosage of many genes, the
adverse effects of which dampen the potential benefits that arise
due to the duplication of gene(s) conferring a selective advan-
tage. This was elegantly demonstrated by Yona et al. (2012).
They showed that whole-chromosome copy-number changes
are a transient occurrence in adaptive evolution experiments.
They provide a quick means of adapting to a continuous selec-
tive pressure that is replaced over time by more subtle genetic
changes that achieve the same goal (Yona et al., 2012). Diploid
budding yeast grown continuously at an elevated temperature
of 39C developed trisomy of chromosome 3. This aneuploidy
was lost once the cells were returned to growth at normal
temperature (30C). Loss of the trisomy occurred not only
when the selective pressure was removed but even when cells
were kept at 39C for extended periods. After 1,000 generations,
trisomy 3 was replaced by increased expression of 17–18 genes
located on chromosome 3 and presumably of genes elsewhere
in the genome that conveyed increased temperature tolerance.
Interestingly, there was a significant overlap in upregulated
genes among four repetitions. These results indicate that
whole-chromosome aneuploidies can provide an effective
means of quickly adapting to a selective pressure. This is not
surprising given that chromosome loss rates are by three orders
of magnitude higher than mutation rates (105 compared
to 108). Eventually, however, the ‘‘crude’’ whole-chromosome
gain/loss solutions are replaced by ones that do not bring with
them the adverse effects caused by gene-dosage changes of
the other genes located on the gained/lost chromosome.
Figure 6. Small- and Large-Scale Gene Copy-Number Alterations
Arise during Adaptive Evolution Experiments
(A) Eight S. cerevisiae strains were isolated after growth under glucose-limiting
conditions for 100–500 generations, and DNA content was assessed. Red and
green indicate gene copy-number amplification and reduction, respectively.
HXT6 encodes a high-affinity hexose transporter and is amplified in evolved
strains E1, E5, and E8. Data from Dunham et al. (2002).
(B) Trisomy 3 is a transient intermediate during continuous growth at 39C.
Cells were grown for 450 generations at 39C. Many isolates harbored an
additional copy of chromosome 3. Upon return to the permissive temperature
(30C), the trisomy was quickly lost. The trisomy was also lost after continuous
growth at 39C (1,000 generations) and replaced by changes in the expression
of genes that confer resistance to high temperature.Recent studies in mice indicate that aneuploidy is also an
effective way to adapt to selective pressure in multicellular
organisms. The liver is a naturally aneuploid organ (Duncanet al., 2010; Putkey et al., 2002; Weaver et al., 2007; described
in detail below), providing an opportunity to determine the impor-
tance of aneuploidy in adaptation to selective pressure. Defi-
ciency of fumarylacetoacetate hydrolase (FAH) causes chronic
liver disease that is suppressed by the loss of enzymes func-
tioning upstream of FAH, such as homogentisic acid dioxyge-
nase (HPD). Mice lacking FAH function and heterozygous for
a deletion in HPD develop disease resistance through loss of
the chromosome encoding the functional copy of HPD (Duncan
et al., 2012), illustrating the power of aneuploidy in providing
adaptive potential even in multicellular organisms.
Mutations that suppress the adverse effects of large-scale
DNA copy-number changes may enhance the adaptive potential
of chromosome gains or losses. Aneuploidy-toleratingmutations
have been found in yeast (Torres et al., 2010). Loss of p53
increases survival of cells following chromosome missegrega-
tion in mammalian cells (Janssen et al., 2011; Li et al., 2010;
Thompson and Compton, 2010). It will be interesting to examine
the contribution of different aneuploidy-tolerating mutations to
disease progression in cancer where gene copy-number alter-
ations are a key feature. Indeed, p53 inactivation is a major con-
tributor to tumorigenesis (Dai and Gu, 2010; Kruse and Gu, 2009;
Toledo and Wahl, 2006).
Gene Copy-Number Alterations as Part of Normal
Development
Differentiation into specific cell types often requires increased
expression of particular genes. In some instances, this is
achieved by amplification of specific loci. Ribosomal DNA
(rDNA) amplification occurs in amphibian oocytes, the macronu-
cleus of Tetrahymena, and budding yeast (Brown and Dawid,
1968; Claycomb and Orr-Weaver, 2005; Gall, 1968; Kobayashi
et al., 1998; Nordman and Orr-Weaver, 2012; Oakes et al.,
2006; Pesin and Orr-Weaver, 2008; Yao et al., 1974) and thus
appears to be a common mechanism used to accommodate
different protein-synthesis needs in different tissues and under
changing environmental conditions. Although rDNA amplifica-
tion is not uncommon, amplification of selective genes is rarely
used to upregulate gene expression and, in the instances where
this has been described, occurs in cells destined to die. In
Drosophila, follicle cells amplify the chorion genes, which
encode eggshell proteins (Spradling, 1981). This amplification
allows follicle cells to make the eggshell. Once they have accom-
plished this task, they become part of the eggshell.
Whole-chromosome aneuploidies have been found in various
tissues in mammals. In mice and humans, 30% of neuroblasts
in the embryonic brain are aneuploid (Rehen et al., 2001). The
majority of these aneuploid neurons are eliminated during devel-
opment, but 10% of neurons in adult brains are estimated to be
aneuploid (Rehen et al., 2001, 2005;Westra et al., 2008). The bio-
logical significance and the impact of this increased aneuploidy
on neuronal physiology and fitness remain to be determined.
Mammalian hepatocytes acquire whole-chromosome gains
and losses during aging and in response to toxic stresses and
disease (Duncan et al., 2010; Putkey et al., 2002; Weaver et al.,
2007). Aneuploidy in hepatocytes is preceded by polyploidiza-
tion as a result of failed cytokinesis. Polyploid cells that harbor
not only additional genome copies but also additional cen-
trosomes then undergo a mitotic division in which allCell 152, January 31, 2013 ª2013 Elsevier Inc. 401
centrosomes form a multipolar spindle to produce aneuploid
progeny. Whether aneuploid liver cells are as fit as their euploid
counterparts remains to be determined, but aneuploidy has
been hypothesized to provide genetic variation so that the
liver can adapt to nutritional and noxious challenges (Duncan
et al., 2010). Determining the importance of aneuploidy in the
function of tissues such as the brain and the liver and
defining whether different cell types exhibit different sen-
sitivities to gene copy-number changes will provide critical
insights into how gene CNVs contribute to cell-type speci-
fication and diseases such as cancer, in which aneuploidy
is the norm, yet fitness as judged by unrestricted proliferation
is high.
Future Directions—Gene Copy-Number Alterations as
a Therapeutic Target?
The last decade has brought to light the importance of gene
copy-number changes in a wide variety of human diseases.
Understanding in detail how changes in copy number of indi-
vidual genes or large chromosomal regions enhance or perhaps
suppress disease is a critical challenge. With an ever-more
detailed view of the human genome and its variations in the
normal population and in disease-prone families, we will be
able to learn which copy-number changes don’t matter and
can focus on those that impact function.
A particularly exciting future direction is the pursuit of gene
copy-number changes in developing therapies. The realization
that CNVs contribute to difficult-to-treat diseases, such as
neurological and psychiatric disorders, brings with it the possi-
bility of targeting the gene products amplified/deleted in partic-
ular disorders. For example, duplication of AUTS4, a gene
encoding the GABAA receptor subunit, has been associated
with autism spectrum disorder (Zhang et al., 2009). Autistic
individuals with this CNV may benefit from compounds that
downregulate GABAA receptor function. CNVs causing disrup-
tions of MYT1L, CTNND2, and ASTN2 have been seen in
patients with Schizophrenia. Crohn’s disease, a bowl inflamma-
tory disease, is linked to copy-number reduction of HBD2.
Compounds that increase the function of the remaining copy
or inhibit the function of negative regulators of the pathways
that these genes function in may have a significant therapeutic
index.
Cancer is the prime example in which gene amplifications and
deletions have been shown to drive disease (Gordon et al.,
2012). Therapies where overexpressed or amplified oncogenic
drivers are targeted have been developed. The gene encoding
epidermal growth factor receptor (EGFR) is amplified in non-
small-cell lung cancer. Small molecules such as gefitinib or erlo-
tinib have been applied to inhibit EGFR with success (Carling,
2004; Paez et al., 2004). ERBB2, which encodes the EGFR
HER2, is amplified in 30% of primary breast cancers (Slamon
et al., 1987). Trastuzumab, an anti-HER2 antibody, has been
used in the therapy of HER2-amplified breast cancers with great
success (Baselga et al., 1998). These successes raise the
exciting possibility that targeting amplified disease drivers
provides opportunities for therapy in cancer, psychiatric disor-
ders, and autoimmune diseases, where effective treatments
are scarce.402 Cell 152, January 31, 2013 ª2013 Elsevier Inc.Whether large-scale gene copy-number changes that cause
Down syndrome or occur in cancer can be targeted in therapy
remains to be determined. In Down syndrome, gene-dosage
changes of many different genes contribute to the associated
phenotypes, making the development of therapeutics a chal-
lenge. The identification of individual genes responsible for
specific phenotypes could enable the development of thera-
peutics that target specific aspects of the condition. For
example, individuals with Down syndrome could benefit from
therapies that lower APP protein levels, to prevent early onset
Alzheimer’s disease; the development of which has, unfortu-
nately, failed so far.
In cancer, the situation is even more complex. In this disease,
the contribution of gene-dosage changes of many genes is
augmented by the variability of an ever-changing genetic
make-up. Many cancers do, however, harbor specific aneu-
ploidies that could be targeted in therapy. For example, trisomy
8 is frequently observed in patients with AML and associated
with poor survival when present together with other genetic
aberrations (Wolman et al., 2002). Drugs that target cells with
amplified chromosome 8 may aid in the treatment of AML.
Genomic instability in cancers also leads to loss of many
genomic regions. These genetic lesions could provide additional
therapeutic targets (Nijhawan et al., 2012). The general stress
phenotypes associated with aneuploidy could also be explored
in cancer treatment. The advantage of such compounds is that
they would show efficacy against a broad spectrum of cancers.
Compounds that preferentially inhibit the proliferation of
aneuploid cell lines have been shown to exist and appear to
exaggerate the general stress phenotypes associated with
whole-chromosome copy-number changes (Tang et al., 2011).
These compounds included AICAR, an agonist of the stress-
activated AMP kinase, and the Hsp90 inhibitor 17-AAG (Tang
et al., 2011). Thus, targeting the general stresses associated
with aneuploidy could be developed as cancer drug targets. It
is worth noting that Hsp90 inhibitors such as 17-AAG display
antitumor efficacy in HER2/ErbB2-positive breast cancer and
are currently in phase II and III clinical trials. The proteasome
inhibitor bortezomib is used in the treatment of multiple myeloma
(Richardson et al., 2005). Other inhibitors of the ubiquitin-
proteasome system such as highly specific inhibitors of the
proteasome-associated deubiquitinating enzyme Usp14 (Lee
et al., 2010) could also show efficacy against aneuploid cells
and thus could be used in the treatment of aneuploid cancers.
We note that, compounds that target aneuploid cells may be
especially effective when combined with chemotherapeutics,
such as Taxol, that increase chromosome missegregation.
Changes in gene copy number, large and small in scale,
contribute to population diversity and are significant contributors
to disease. Understanding their cost and benefits will provide
critical insights into evolution and diseases.
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